Braveheart Bio, Inc. (BRVE) Ownership
BRVE ownership summary
as of October 17, 2026- Institutions
- 27.9% of shares outstanding
- Insiders
- 58.16% of shares outstanding
- Shares outstanding
- 90.0M
- Float
- 12.7M shares available to trade
- Short interest
- — 4.1M shares short
- Days to cover
- 6.92 short interest up 67.8% vs prior month
- Institutions 27.92%
- Insiders 58.16%
- Other investors 13.92%
BRVE top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Fidelity Growth Company Fund | 1.10% | 780K | $14.6M | +779,600 (0.0%) | August 31, 2026 |
| 2 | Strategic Advisers Fidelity US TtlStk | 0.85% | 600K | $11.2M | +600,000 (0.0%) | August 31, 2026 |
| 3 | Fidelity Select Health Care | 0.76% | 537K | $10.1M | +537,444 (0.0%) | August 31, 2026 |
| 4 | MFS New Discovery I | 0.49% | 346K | $6.5M | +345,984 (0.0%) | August 31, 2026 |
| 5 | Fidelity Advisor Health Care I | 0.38% | 266K | $5.0M | +265,638 (0.0%) | August 31, 2026 |
| 6 | Fidelity Select Biotechnology | 0.37% | 260K | $4.9M | +259,919 (0.0%) | August 31, 2026 |
| 7 | Fidelity Series Stk Selec Lg Cp Val | 0.34% | 238K | $4.5M | +238,100 (0.0%) | August 31, 2026 |
| 8 | Fidelity Growth Company K6 | 0.32% | 224K | $4.2M | +223,700 (0.0%) | August 31, 2026 |
| 9 | Fidelity Series Growth Company | 0.27% | 188K | $3.5M | +187,500 (0.0%) | August 31, 2026 |
| 10 | T. Rowe Price Small-Cap Value | 0.25% | 178K | $3.3M | +178,220 (0.0%) | August 31, 2026 |
| 11 | Fidelity Stock Selec | 0.25% | 176K | $3.3M | +175,791 (0.0%) | August 31, 2026 |
| 12 | Fidelity Advisor Biotechnology I | 0.25% | 174K | $3.3M | +174,449 (0.0%) | August 31, 2026 |
| 13 | MFS VIT New Discovery Init | 0.18% | 128K | $2.4M | +128,029 (0.0%) | August 31, 2026 |
| 14 | BlackRock Health Sciences Opps Inv A | 0.17% | 117K | $2.2M | +117,028 (0.0%) | August 31, 2026 |
| 15 | Schwab US Small-Cap ETF™ | 0.16% | 116K | $2.2M | +72 (+0.1%) | September 30, 2026 |
| 16 | Fidelity VIP Health Care Initial | 0.14% | 98K | $1.8M | +98,472 (0.0%) | August 31, 2026 |
| 17 | Strategic Advisers U.S. Total Stock | 0.12% | 82K | $1.5M | +82,374 (0.0%) | August 31, 2026 |
| 18 | Fidelity VIP Stock Selector Initial | 0.11% | 80K | $1.5M | +80,000 (0.0%) | August 31, 2026 |
| 19 | Vanguard MStar Total Stk Mkt Idx Invest | 0.06% | 43K | $805,353 | +43,044 (0.0%) | August 31, 2026 |
| 20 | BlackRock Advantage Small Cap Core Instl | 0.04% | 26K | $494,337 | +26,421 (0.0%) | August 31, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
Who owns BRVE
Institutional investors own 27.9% of Braveheart Bio's shares and insiders 58.16%.
Related: BRVE analyst forecast. See the BRVE stock overview for the latest quote and news.
BRVE ownership FAQ
What percentage of Braveheart Bio is owned by institutions?
Institutions hold 27.9% of Braveheart Bio's shares outstanding; insiders hold 58.16%.
Which funds own Braveheart Bio?
The largest fund holders of Braveheart Bio are Fidelity Growth Company Fund (1.10%), Strategic Advisers Fidelity US TtlStk (0.85%), Fidelity Select Health Care (0.76%), MFS New Discovery I (0.49%), Fidelity Advisor Health Care I (0.38%).
How many shares of Braveheart Bio are outstanding?
Braveheart Bio has 90.0M shares outstanding, of which 12.7M are in the public float.